WA-VIRTUOZZO
13.10.2021 13:02:12 CEST | Business Wire | Press release
Virtuozzo , a global leader in high-efficiency virtualization and hyperconverged software solutions, today announced its collaboration with DT Technology Group has accelerated DT’s transition from a leading telco to a leading digital platform enabler. Through the use of Virtuozzo Hybrid Infrastructure , DT has deployed a Public Cloud as well as new revenue streams via DevOps services—all while reducing its total cost of ownership by 30 percent.
Increasingly, companies seek to leverage digital solutions to transform their businesses. Simultaneously, SmartCity projects show no signs of slowing down. However, the continued growth of 5G connectivity and IoT applications brings with it new infrastructure design challenges—integration of AI computing, Cloud Native applications, GPU computing, application modernization, and DevOps resources. The supporting network infrastructure must be robust enough to scale with the demand while the software development ecosystem around it must be mature enough to enable enterprises as well as small- to medium-sized companies to leverage the technology trends for business gain.
Drawing on its ICT system integration and telecom roots, DT sought to address both needs by building an enterprise-grade and 5G-ready infrastructure as well as establishing a team of skilled digital software developers. In the late 2010’s, the company launched its Cloud platform and digital software solutions suite via partnerships with a hyperscaler and proprietary virtualization solutions provider, though quickly sought to replace them… and did with a single partner: Virtuozzo.
“We have a unique market opportunity. We understand the infrastructure requirements behind carrier grade platforms and are leveraging this expertise to build seamless, elastic enterprise-grade digital platforms,” said Tolga Dinçer, CEO, DT Technology Group. “Our initial partner choices, however, limited what we could deliver to customers as they were complicated to use, inflexible, and quite expensive. Virtuozzo Hybrid Infrastructure solved all of those problems out of the box.”
A Public Cloud for Modern Times
DT uses the OpenStack-based Virtuozzo Hybrid Infrastructure to host a robust 5G-enabled infrastructure supporting Public Cloud, Edge data centers, and OnPrem needs. The Cloud infrastructure scales easily and notably taps into local data centers to satisfy data sovereignty requirements. Further, its inherent capabilities driven by Virtuozzo’s hyperconverged system include support for various advanced solutions—from graphics-rich VDI services to compute-heavy, AI-dependent big data analytics.
A Digital Platform Partner for the DevOps Community
To help businesses capitalize on its robust infrastructure, DT also uses Virtuozzo’s software to deliver digital solutions. This offering includes consultative services as well as digital platform development—such as microservices architecture design—for cross-industry customers, and depends heavily on Virtuozzo Hybrid Infrastructure’s core features:
- Security and business continuity
- Production-ready Kubernetes environment and tools
- Flexible licensing models (PAYG pricing)
- Immediate scalability, up or down
- Storge-as-a-Service
- Hardware vendor agnostic
“Virtuozzo is purpose-built to help companies like DT shift their and their customers’ business models from capex to opex, helping reduce costs while gaining the benefits of hyperconverged, Cloud-driven digital transformation,” said Alex Fine, Virtuozzo CEO. “We’re seeing increased adoption of our technology by savvy service providers striving to deliver alternative Cloud services: services that compete with those of hyperscalers in diversity, performance and capabilities, but are simpler, more flexible, and far more cost-efficient to use. To that end, DT is optimizing Virtuozzo Hybrid Infrastructure to an incredible extent. We’re excited to see what they’ve accomplished to date and are proud to be a part of their continued journey.”
About DT Technology Group
Headquartered in Istanbul, DT Technology Group (www.dt.net.tr ) is an international digital platform enabler servicing Turkey and other locations worldwide. Since its 2006 inception, DT has evolved from being an ICT systems integrator to a telco responsible for thousands of installations of carrier network infrastructure for 2G through to 5G networks. In 2018, the company packaged its experience to create an enterprise-grade, 5G-ready multiregional Public Cloud offering.
About Virtuozzo
Virtuozzo (www.virtuozzo.com ) is a leading, global provider of hybrid virtualization, storage, and cloud enablement software solutions. The Company's software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The Company provides software solutions and services to over 750 service providers, ISVs, and enterprises worldwide to enable hundreds of thousands of virtual environments, running mission-critical cloud workloads. A significant force in the open-source community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU, and the Linux kernel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005219/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom